Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313374743> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W4313374743 endingPage "92.43" @default.
- W4313374743 startingPage "92.43" @default.
- W4313374743 abstract "Abstract Recurrent Uveitis (RU), is a relapsing/remitting disease that accounts for more than 10% of severe visual handicaps in US patients per year, despite treatments that often include steroids. Even when effective, prolonged steroid use is accompanied by significant negative side effects. As such, there is a critical need for the development of novel therapeutic strategies to treat RU. Notably, equine recurrent uveitis (ERU) is the only spontaneous model of human recurrent uveitis, and is also a leading cause of equine blindness. RU is driven by aberrant inflammation from the immune system. Notably, the body naturally generates a family of intracellular proteins, known as suppressors of cytokine signaling (SOCS), which prevent excessive inflammatory responses. We have previously shown that topical application of an eye drop, containing a cell-penetrating peptide that mimics SOCS1 (SOCS1-KIR), could mitigate experimental uveitis in mice. In order to evaluate the ability to translate our preclinical findings we conducted a first in equine, open label study in which we evaluated the safety and efficacy of topical SOCS1 peptide administration in ERU patients. We found that topical SOCS1-KIR administration was well tolerated in equine patients. Moreover, topical administration of SOCS1-KIR peptide twice a day was associated with reductions in ocular discomfort, hyperemia, and aqueous flare. Additionally, biochemical analyses of SOCS1-KIR revealed an enrichment strategy that could potentially be utilized to optimize ocular peptide dosing. Together, these results prove justification for conducting larger additional treatment studies in horses, and exploring SOCS1-KIR use in humans." @default.
- W4313374743 created "2023-01-06" @default.
- W4313374743 creator A5001546515 @default.
- W4313374743 creator A5013188713 @default.
- W4313374743 creator A5042211335 @default.
- W4313374743 creator A5046998898 @default.
- W4313374743 creator A5047320885 @default.
- W4313374743 creator A5047616164 @default.
- W4313374743 creator A5049412375 @default.
- W4313374743 creator A5068734542 @default.
- W4313374743 creator A5088031712 @default.
- W4313374743 creator A5091802012 @default.
- W4313374743 date "2020-05-01" @default.
- W4313374743 modified "2023-10-01" @default.
- W4313374743 title "Mitigation of Equine Recurrent Uveitis through topical Suppressor of Cytokine signaling-1 (SOCS1) mimetic peptide: Open Label Safety and Efficacy Pilot study" @default.
- W4313374743 doi "https://doi.org/10.4049/jimmunol.204.supp.92.43" @default.
- W4313374743 hasPublicationYear "2020" @default.
- W4313374743 type Work @default.
- W4313374743 citedByCount "1" @default.
- W4313374743 countsByYear W43133747432022 @default.
- W4313374743 crossrefType "journal-article" @default.
- W4313374743 hasAuthorship W4313374743A5001546515 @default.
- W4313374743 hasAuthorship W4313374743A5013188713 @default.
- W4313374743 hasAuthorship W4313374743A5042211335 @default.
- W4313374743 hasAuthorship W4313374743A5046998898 @default.
- W4313374743 hasAuthorship W4313374743A5047320885 @default.
- W4313374743 hasAuthorship W4313374743A5047616164 @default.
- W4313374743 hasAuthorship W4313374743A5049412375 @default.
- W4313374743 hasAuthorship W4313374743A5068734542 @default.
- W4313374743 hasAuthorship W4313374743A5088031712 @default.
- W4313374743 hasAuthorship W4313374743A5091802012 @default.
- W4313374743 hasConcept C121608353 @default.
- W4313374743 hasConcept C126322002 @default.
- W4313374743 hasConcept C14077384 @default.
- W4313374743 hasConcept C179185449 @default.
- W4313374743 hasConcept C203014093 @default.
- W4313374743 hasConcept C2776194053 @default.
- W4313374743 hasConcept C2776914184 @default.
- W4313374743 hasConcept C2778690821 @default.
- W4313374743 hasConcept C2779281246 @default.
- W4313374743 hasConcept C55493867 @default.
- W4313374743 hasConcept C71924100 @default.
- W4313374743 hasConcept C86803240 @default.
- W4313374743 hasConcept C98274493 @default.
- W4313374743 hasConceptScore W4313374743C121608353 @default.
- W4313374743 hasConceptScore W4313374743C126322002 @default.
- W4313374743 hasConceptScore W4313374743C14077384 @default.
- W4313374743 hasConceptScore W4313374743C179185449 @default.
- W4313374743 hasConceptScore W4313374743C203014093 @default.
- W4313374743 hasConceptScore W4313374743C2776194053 @default.
- W4313374743 hasConceptScore W4313374743C2776914184 @default.
- W4313374743 hasConceptScore W4313374743C2778690821 @default.
- W4313374743 hasConceptScore W4313374743C2779281246 @default.
- W4313374743 hasConceptScore W4313374743C55493867 @default.
- W4313374743 hasConceptScore W4313374743C71924100 @default.
- W4313374743 hasConceptScore W4313374743C86803240 @default.
- W4313374743 hasConceptScore W4313374743C98274493 @default.
- W4313374743 hasIssue "1_Supplement" @default.
- W4313374743 hasLocation W43133747431 @default.
- W4313374743 hasOpenAccess W4313374743 @default.
- W4313374743 hasPrimaryLocation W43133747431 @default.
- W4313374743 hasRelatedWork W1595298604 @default.
- W4313374743 hasRelatedWork W1788119937 @default.
- W4313374743 hasRelatedWork W2000583211 @default.
- W4313374743 hasRelatedWork W2033215494 @default.
- W4313374743 hasRelatedWork W2069965849 @default.
- W4313374743 hasRelatedWork W2073308867 @default.
- W4313374743 hasRelatedWork W2094203902 @default.
- W4313374743 hasRelatedWork W2374119114 @default.
- W4313374743 hasRelatedWork W2412190356 @default.
- W4313374743 hasRelatedWork W4220899746 @default.
- W4313374743 hasVolume "204" @default.
- W4313374743 isParatext "false" @default.
- W4313374743 isRetracted "false" @default.
- W4313374743 workType "article" @default.